Brigit Hits New Growth Milestones as it Distributes More Than $2.3B in Cash Advances and Saves Everyday Americans $1B in Overdraft Fees


New York City, April 24, 2024 Brigit, the leading financial health app dedicated to improving financial inclusion in America, announces a series of financial milestones, including $100M in revenue and a full year of profitability, further establishing itself as a leading financial service.

To date, Brigit has advanced $2.3 billion to help members cover essentials like rent and groceries, while saving them $1 billion in predatory bank fees (on average, members save $425 annually in overdraft fees), starkly contrasting with big banks that charged Americans $10 billion in overdraft fees in 2022.

With 75% of adults in the U.S. living paycheck to paycheck, Brigit provides a suite of transparent, fair, and valuable financial products designed to help members access cash, build credit, earn, save, and understand their finances.

AI-Powered Cash Flow Underwriting Eliminates Bias as Scale
At the core of Brigits platform is its proprietary machine learning and AI-powered Cash-flow Underwriting technology, which relies exclusively on cash flow data. This eliminates bias and bypasses outdated FICO scores, which have historically marginalized millions of Americans. Since launching in 2019, Brigit has analyzed trillions of dollars in cash flow transactions, allowing the company to give its members early access to their earned wages 32 million times, totaling $2.3 billion and covering everything from rent and groceries to unexpected emergencies.

Zuben Mathews, CEO of Brigit, explains, We are addressing a crucial societal issue ensuring equitable access to tools that lead to financial health for millions. By fundamentally improving the credit decision-making process, we can extend opportunities to customers whove long been marginalized. Our sole focus is on furthering financial inclusion, and while weve already made a significant contribution to our members, were only just getting started.

Introducing Brigit Premium
In response to our members desire to keep improving their financial health with Brigit, Brigit is announcing the official launch of Brigit Premium today to all members, transitioning it from beta. Brigit Premium is designed to help members build their credit, access earned wages early, budget better, gain valuable financial insights, and find earning and saving opportunities. Credit Builder, the newest addition to Brigits suite of services which is designed to help you to build credit by setting aside savings each month, has helped 100,000+ members. To date, those members credit scores have collectively increased by 4.5 million points.

Priced at $14.99 per month, Brigit Premium includes:

Credit Builder: Whether you have no or bad credit, Credit Builder is designed to help you build credit by setting aside savings each month.
Instant Cash: Get cash in minutes with no credit check, late fees, or Express Delivery fees, as they are all included in the flat monthly subscription.
Credit Monitoring: Stay informed about credit health with regular score updates and access to complete credit reports.
Identity Theft Protection: Up to $1 million in theft reimbursement, lost wallet assistance, and restoration services.
Earn & Save: Discover opportunities to earn money and access exclusive offers, providing additional avenues for financial growth.
Finance Helper: Monitor expenses with spending breakdowns, bill forecasts, and earnings comparisons.

Brigits mission to help Americans build a brighter financial future is grounded in fostering economic sustainability for everyday individuals living paycheck to paycheck. At a time when 40% of American adults reported that they struggled to make ends meet, 93% of Brigit users said they felt in control of their finances after using Brigits services.

Dominique Phillips, Special Education Teacher and Brigit member says, Before using Brigit, I felt frustrated having to decide what was most important to pay for, whether I should go to Urgent Care or buy food. I love the feature that predicts if I will go into the negative; it gives me a clear picture of things I need to work on or change. Knowing how much money Ive spent on a certain area helps me think about whats important to save up for so I have it later. The last time I used Brigit was to pay for my two-year-old daughters daycare, which has to be paid every week, and I needed to pay her so I could go to work.

As the company continues to scale and launch new products, Tara Rider has been appointed Head of Policy and Government Relations, and Anthony Forino Vice President of Compliance. Riders extensive public policy background and consumer rights advocacy will bolster Brigits relationships with policymakers and regulators, emphasizing the companys commitment to impactful governance. Meanwhile, Forinos expertise in compliance and risk management within the financial sector will ensure Brigits continued adherence to regulatory standards, reinforcing its dedication to ethical practices and economic inclusivity.

To learn more, go to:

About Brigit
Brigit is a holistic financial health app that has helped more than 7 million Americans budget better, monitor and build their credit, get their earned wages early, protect themselves from identity theft, and find ways to earn and save money. Its mission is to help everyday Americans build a better financial future. Brigit is backed by Ashton Kutcher and Kevin Durant, as well as other prominent investors.

Hong Kong – DH to adopt new growth charts in second half of 2024 (with photo)

DH to adopt new growth charts in second half of 2024 (with photo)


     ​The Department of Health (DH) today (April 22) announced that a new set of growth charts, i.e. the Hong Kong 2020 Growth References (HK2020), with new references and definitions will be adopted by the DH starting from the second half of this year as a better tool to assess and monitor the growth of children and adolescents.

     A spokesman for the DH said that growth charts serve as an important reference tool for clinical assessment of an individual child, and facilitate the monitoring of growth trends of the entire population of children and the timely adjustment of public health measures and strategies on enhancing children’s health. To study the growth of contemporary Hong Kong children and review the existing growth charts developed in 1993 (HK1993), the DH, the Department of Paediatrics of the Chinese University of Hong Kong, and the Department of Paediatrics and Adolescent Medicine of the University of Hong Kong jointly conducted the Hong Kong Growth Study (HKGS) which was funded by the Health and Medical Research Fund (HMRF) of the Health Bureau. The research team also reviewed whether the Child Growth Standards developed by the World Health Organization for children 0 to 5 years old in 2006 (WHO2006) was suitable to be adopted for use in Hong Kong.

     The key characteristics of the HKGS and the development of the HK2020 include the following:

  1. The study was funded by the HMRF of the Health Bureau. The HMRF has been supporting various health and medical research to inform health policies and improve population health through evidence-based scientific knowledge;
  2. Apart from the funding from the HMRF, the HKGS reviewed and analysed the growth data of over two million local children collected by the DH’s Family Health Service and Student Health Service. In addition, a population-based growth survey was conducted from 2019 to 2022, with growth data collected from over 21 300 infants, children and adolescents at hospitals, health centres and education institutes; and
  3. The HKGS results revealed a clear secular trend in height for children and adolescents in Hong Kong. Thus a new set of growth charts for child-growth monitoring is required in Hong Kong.

     Based on the data collected in the growth survey and advice from local and overseas experts, four sets of gender-specific growth charts for children 0 to 18 years are developed in the HK2020, namely (1) Weight-for-age charts; (2) Length/height-for-age charts; (3) Body Mass Index (BMI)-for-age charts; and (4) Head circumference-for-age charts. Comparing the new and old growth charts, the weight and height in HK2020 were higher than that in HK1993, particularly at pubertal ages. Notably, an increase of about 2 centimetres in median height was found for boys and girls at the age of 18.

     Moreover, the data of Hong Kong children 0-5 years in the survey also fitted the WHO2006 reasonably well. The HKGS concluded that HK2020 for 0 to 18 years and WHO2006 for 0 to 5 years are suitable for use for Hong Kong children. Also, as  the distribution of body fat for children changes with age, the study recommended an updated definition and assessment for overweight/obesity by using BMI-for-age instead of weight-for-height. The growth assessment in many places (including the Mainland, the United Kingdom and the United States) are also using BMI as a reference. The DH will continue its healthy lifestyle promotion among children and parents and various health promotion programmes (such as the Whole School Health Programme) in order to better prevent and improve the overweight situation of the children.

     To provide an updated reference tool to assess and monitor the growth of children and adolescents, the DH will adopt the HK2020 at its Maternal and Child Health Centres (MCHCs) and Student Health Service Centres (SHSCs) for growth monitoring of children aged 0 to 5 years and 6 to 18 years respectively. The new growth charts are expected to be deployed in July this year for MCHCs and in September this year for SHSCs. Starting from September this year, the Hospital Authority will implement the new growth charts in its hospitals in phases, with a view to rolling out to all its hospitals by end of 2024. The District Health Centres currently providing services targeted at children, including group classes and outreach health risk assessment, will also support the launching of the new growth charts. In addition, the DH will also send letters to healthcare professional bodies and stakeholders to inform them of the study and the new growth charts. Moreover, the new growth chart shall also be made available in the eHealth app for use and viewing.

     Relevant information of the study will be made available at the HKGS website as well as the website of DH for reference and use by professionals. For more information on the updated set of growth charts, please visit and

Japan – Boosting Growth Investment to Power Mobility Company Transformation Toyota-DENSO Capital Ties Revised

Toyota Motor Corporation (Toyota) has decided to sell a portion of its shareholdings in DENSO CORPORATION (DENSO).

Toyota has been restructuring its groupwide business with a “home & away” perspective since 2016. This is part of its transformation into a mobility company, stimulating mutual improvement through greater collaboration with highly specialized group companies. Amid these efforts, the core group companies of Toyota, DENSO, Toyota Industries Corporation, and Aisin Corporation have held extensive discussions and have come to an agreement that, to start, Toyota will sell a portion of its shares in DENSO. By effectively leveraging funds obtained through the sale, Toyota can boost capital efficiency and achieve further growth for the Group, while maintaining the capital ties that have sustained a strong relationship. DENSO will continue to strengthen the Toyota Group’s competitiveness as a leader in software. Toyota plans to use the generated capital to make growth investments focused on electrification, intelligence, and diversification initiatives.

Toyota also intends to carefully review its capital ties with other group companies on an individual basis, examining elements such as human resources, operations, culture, and business relationships while exploring the potential for strengthening competitiveness. The Group will continue working as one to drive Toyota’s transformation into a mobility company.

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

A closer examination at JinMed’s top-line growth trajectory, revealing an abundance growth potential

With the positive indications in the US stock market, Chinese concept stocks have gotten significant attention. Among them, Jin Medical International Ltd. (“JinMed” or the “Company”, NASDAQ: ZJYL), a emerging player in the medical equipment sector, delivered exceptional performance that exceeded industry benchmarks last month.  In addition to receiving market recognition of its wheelchair business, there is even greater anticipation regarding the company’s strategic development and management team’s execution capabilities.

Upon closer examination of JinMed’s recent financial performance, its revenue is not as undesirable as recently discussed. Despite a slight decrease in revenue for the fiscal year 2022 compared to the fiscal year 2021, there was still a commendable growth of 19% compared to the fiscal year 2020. This achievement is particularly noteworthy given the stringent policies and trade measures implemented during the COVID-19 pandemic in 2022, underscoring JinMed’s clear overall revenue growth trend.

Taking a further examining at this interim report following the easing of the pandemic, while the report reveals a year-on-year revenue growth of only 8.3% and a net profit growth of 44.1% for the first half of 2023, it is important to consider that the financial report is denominated in US dollars, without factoring in the impact of foreign exchange gains or losses. In reality, excluding external factors, JinMed witnessed an impressive increase by 18.7% and net profit by 57.9% during the first half of the fiscal year 2023, signifying its consistent out-performance industry average growth the past three years.

After analyzing the revenue performance, let us delve into the growth prospects. The aging population in both China and Japan has created a consistent demand for medical assistive devices, particularly wheelchairs. According to a report by Frost & Sullivan, the total sales of wheelchairs in Japan have witnessed a compound annual growth rate of 12.2% from 2016 to 2020. Projections indicate that this growth rate is expected to further escalate to a remarkable 21.3% over the next five years. Considering China and Japan’s status as pivotal markets for JinMed, these prospects highlight substantial opportunities for advancement.

According to the company’s prospectus and recent disclosures, JinMed is actively expanding its sales channels and business scope. On one hand, it is proactively expanding its research and development efforts, further establishing its presence in the wheelchair market segment. This includes the development of a new generation of ultra-lightweight portable electric wheelchairs, thereby enhancing the market competitiveness of its core products. On the other hand, the company has also expressed its intention to strengthen sales in both European and American markets. Furthermore, it has embarked on ventures related to developing shared wheelchair-related infrastructure and other shared medical products, breaking away from solely selling shared wheelchairs to customers as done previously. Additionally, leveraging its strengths, the company is diversifying into various businesses such as domestic elderly electric mobility vehicles, intelligent bathing products, beauty products, and respiratory devices.

JinMed’s interim report for this year has successfully overcome the challenges posed by external factors. With the further expansion of the wheelchair market and diversification of business development, there exists immense potential for revenue growth. Given the high expectations for an increase, the company’s high valuation is a justified reflection of its performance.

Topic: Press release summary

Sectors: BioTech, Healthcare & Pharm

From the Asia Corporate News Network

Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Canada – 1-Aminocyclopropanecarboxylic acid, VBC-30452 SG Plant Growth Regulator, Accede SG Plant Growth Regulator, Proposed Registration Decision (PRD2023-03)

Health Canada’s Pest Management Regulatory Agency (PMRA), under the authority of the Pest Control Products Act, is proposing registration for the sale and use of ACC Technical Powder, VBC-30452 SG Plant Growth Regulator and Accede SG Plant Growth Regulator, containing the technical grade active ingredient 1-aminocyclopropanecarboxylic acid, for commercial fruit tree thinning for apple trees.

How to get involved
This consultation is open for comment from 21 March 2023 to 5 May 2023 (45 calendar days). Open the Consultation Summary to access the document.

If you would like to comment, see the Pest Management Regulatory Agency Publications Section page for contact information. Please be sure to include the title of the consultation document on which you are commenting. Interested parties are encouraged to provide comments by 5 May 2023.

Reporting to Canadians
Health Canada will make the results of this consultation available on this website. Once the decision on 1-aminocyclopropanecarboxylic acid, VBC-30452 SG Plant Growth Regulator, Accede SG Plant Growth Regulator is finalized, the PMRA will post a Registration Decision on the Pesticides and Pest Management Reports and Publications portion of

If you have any questions, contact the Pest Management Information Service.

Interested in our other consultations? Sign up and stay informed about topics that matter to you.